{"id":"budesonide-inhalant","safety":{"commonSideEffects":[{"rate":"10%","effect":"Oral thrush"},{"rate":"5%","effect":"Headache"},{"rate":"5%","effect":"Cough"}]},"_chembl":{"chemblId":"CHEMBL1370","moleculeType":"Small molecule","molecularWeight":"430.54"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Budesonide acts as a glucocorticoid receptor agonist, which reduces inflammation and immune responses.","oneSentence":"Glucocorticoid receptor agonist","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:22:58.543Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma"},{"name":"Chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT06940700","phase":"PHASE2","title":"Clinical Study on the Efficacy and Safety of SHR-4597 Inhalant in Adult Patients With Asthma","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Hengrui Pharmaceutical Co., Ltd","startDate":"2025-04","conditions":"Asthma","enrollment":60},{"nctId":"NCT05148312","phase":"PHASE1","title":"Single-dose AQ001S PK Study in Healthy Volunteers","status":"COMPLETED","sponsor":"Aquilon Pharmaceuticals S.A.","startDate":"2021-11-12","conditions":"Pharmacokinetics","enrollment":29},{"nctId":"NCT04027322","phase":"PHASE2, PHASE3","title":"Inhaled Steroids for Acute Pharyngitis.","status":"COMPLETED","sponsor":"Oman Medical Speciality Board","startDate":"2019-06-01","conditions":"Acute Pharyngitis","enrollment":200},{"nctId":"NCT00159263","phase":"NA","title":"Effect of Symbicort on GR Localisation in Asthma","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2004-11","conditions":"Asthma","enrollment":10},{"nctId":"NCT03504527","phase":"NA","title":"Efficiency of Budesonide Combined With Formoterol and Tiotropium in the Treatment of Acute Exacerbation of ACO","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2018-05-01","conditions":"Asthma-COPD Overlap","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Budesonide inhalant","genericName":"Budesonide inhalant","companyName":"Guangdong Hengrui Pharmaceutical Co., Ltd","companyId":"guangdong-hengrui-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Budesonide inhalant is a small molecule glucocorticoid receptor agonist used to treat conditions such as asthma, acute pharyngitis, and asthma-COPD overlap. It is classified as an agonist in the drug class and is administered via inhalation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}